Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the clinical outcomes utilizing revascularization and aggressive drug evaluation [COURAGE] trial)

American Journal of Cardiology

Volumn 111, Issue 11, 2013, Pages 1557-1562

  Maron, David J ^a   Hartigan, Pamela M ^b   Neff, David R ^c   Weintraub, William S ^d   Boden, William E ^e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Veterans   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d CHRISTIANA CARE HEALTH SYSTEM   (United States)

^e STRATTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84877835829     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.02.005     Document Type: Article

References (22)

1. W.E. Boden, R.A. O'Rourke, K.K. Teo, P.M. Hartigan, D.J. Maron, W. Kostuk, M. Knudtson, M. Dada, P. Casperson, C.L. Harris, J.A. Spertus, L. Shaw, B.R. Chaitman, G.B. Mancini, D.S. Berman, G. Gau, and W.S. Weintraub The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Am J Cardiol 99 2007 208 212
2. W.E. Boden, R.A. O'Rourke, K.K. Teo, P.M. Hartigan, D.J. Maron, W. Kostuk, M. Knudtson, M. Dada, P. Casperson, C.L. Harris, J.A. Spertus, L. Shaw, B.R. Chaitman, G.B. Mancini, D.S. Berman, and W.S. Weintraub Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program No. 424 Am Heart J 151 2006 1173 1179
3. D.J. Maron, W.E. Boden, R.A. O'Rourke, P.M. Hartigan, K.J. Calfas, G.B.J. Mancini, J.A. Spertus, M. Dada, W.J. Kostuk, M. Knudtson, C.L. Harris, S.P. Sedlis, R.G. Zoble, L.M. Title, G. Gosselin, S. Nawaz, G.T. Gau, A.S. Blaustein, E.R. Bates, L.J. Shaw, D.S. Berman, B.R. Chaitman, W.S. Weintraub, K.K. Teo, and COURAGE Trial Research Group Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial J Am Coll Cardiol 55 2010 1348 1358
4. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr., and N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
5. K.J. Calfas, B.J. Long, J.F. Sallis, W.J. Wooten, M. Pratt, and K. Patrick A controlled trial of physician counseling to promote the adoption of physical activity Prev Med 25 1996 225 233
6. K. Calfas, and A. Hagler Health promotion in practice S. Gorin, Physcial Activity 2006 Jossey-Bass San Francisco, California 192 221
7. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
8. H. Mochari, Q. Gao, and L. Mosca Validation of the MEDFICTS dietary assessment questionnaire in a diverse population J Am Diet Assoc 108 2008 817 822
9. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Circulation 89 1994 1333 1445
10. S.C. Smith Jr., J. Allen, S.N. Blair, R.O. Bonow, L.M. Brass, G.C. Fonarow, S.M. Grundy, L. Hiratzka, D. Jones, H.M. Krumholz, L. Mosca, R.C. Pasternak, T. Pearson, M.A. Pfeffer, and K.A. Taubert AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
11. W.E. Boden, R.A. O'Rourke, K.K. Teo, P.M. Hartigan, D.J. Maron, W.J. Kostuk, M. Knudtson, M. Dada, P. Casperson, C.L. Harris, B.R. Chaitman, L. Shaw, G. Gosselin, S. Nawaz, L.M. Title, G. Gau, A.S. Blaustein, D.C. Booth, E.R. Bates, J.A. Spertus, D.S. Berman, G.B. Mancini, and W.S. Weintraub Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
12. E.L. Lehman Nonparametrics: Statistical Methods Based on Ranks 1985 Holden-Day New York, New York
13. D.R. Cox, and D. Oakes Analysis of Survival Data 1984 Chapman and Hall London, United Kingdom
14. M.H. Davidson, K.C. Maki, T.A. Pearson, R.C. Pasternak, P.C. Deedwania, J.M. McKenney, G.C. Fonarow, D.J. Maron, B.J. Ansell, L.T. Clark, and C.M. Ballantyne Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am J Cardiol 96 2005 556 563
15. J.M. Foody, S.G. Sajjan, X.H. Hu, D.R. Ramey, D.R. Neff, A.M. Tershakovec, J.E. Tomassini, C. Wentworth, and K. Tunceli Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients J Clin Lipidol 4 2010 126 132
16. J.J. Kastelein, F. Akdim, E.S. Stroes, A.H. Zwinderman, M.L. Bots, A.F. Stalenhoef, F.L. Visseren, E.J. Sijbrands, M.D. Trip, E.A. Stein, D. Gaudet, R. Duivenvoorden, E.P. Veltri, A.D. Marais, and E. de Groot Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443
17. A.J. Taylor, T.C. Villines, E.J. Stanek, P.J. Devine, L. Griffen, M. Miller, N.J. Weissman, and M. Turco Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
18. J.M. Drazen, J.A. Jarcho, S. Morrissey, and G.D. Curfman Cholesterol lowering and ezetimibe N Engl J Med 358 2008 1507 1508
19. A.B. Rossebo, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Barwolf, I. Holme, Y.A. Kesaniemi, W. Malbecq, C.A. Nienaber, S. Ray, T. Skjaerpe, K. Wachtell, and R. Willenheimer Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med e 359 2008 1343 1356
20. C. Baigent, M.J. Landray, C. Reith, J. Emberson, D.C. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig, B. Neal, L. Jiang, L.S. Hooi, A. Levin, L. Agodoa, M. Gaziano, B. Kasiske, R. Walker, Z.A. Massy, B. Feldt-Rasmussen, U. Krairittichai, V. Ophascharoensuk, B. Fellstrom, H. Holdaas, V. Tesar, A. Wiecek, D. Grobbee, D. de Zeeuw, C. Gronhagen-Riska, T. Dasgupta, D. Lewis, W. Herrington, M. Mafham, W. Majoni, K. Wallendszus, R. Grimm, T. Pedersen, J. Tobert, J. Armitage, A. Baxter, C. Bray, Y. Chen, Z. Chen, M. Hill, C. Knott, S. Parish, D. Simpson, P. Sleight, A. Young, and R. Collins The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
21. I. Holme, K. Boman, P. Brudi, K. Egstrup, C. Gohlke-Baerwolf, Y.A. Kesaniemi, W. Malbecq, A.B. Rossebo, K. Wachtell, R. Willenheimer, and T.R. Pedersen Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial Am J Cardiol 105 2010 1802 1808
22. R.M. Califf, Y. Lokhnygina, C.P. Cannon, M.E. Stepanavage, C.H. McCabe, T.A. Musliner, R.C. Pasternak, M.A. Blazing, R.P. Giugliano, R.A. Harrington, and E. Braunwald An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 2010 705 709